Name: ORIC Pharmaceuticals, Inc. (ORIC) Financial Statements
Creator: FinSpry

ORIC Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

ORIC Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	1.11	0.00	0.00	0.00	0.00
Gross Profit	-1.11	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	114.07	85.17	61.68	56.86	60.76
Selling, General & Administrative	28.82	25.61	25.09	22.01	13.42
Operating Expenses	142.90	110.78	86.77	78.87	74.19
Operating Income	-142.90	-110.78	-91.77	-78.87	-74.19
Other Income/Expense
Interest Income	15.05	10.08	2.65	0.14	0.31
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	15.05	10.08	-2.36	-0.02	-0.18
Income
Income Before Tax	-127.85	-100.70	-89.12	-78.72	-73.70
Income Tax Expense	0.00	-6.94	-6.01	-5.38	-5.16
Net Income	-127.85	-100.70	-89.12	-78.72	-73.70
Net Income - Continuous Operations	-127.85	-100.70	-89.12	-78.72	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-141.79	-109.75	-85.80	-77.97	-48.37
EBIT	-142.90	-110.78	-86.77	-78.87	-49.34
Depreciation & Amortization	1.11	1.03	1.00	0.90	1.00
Earnings Per Share
Basic EPS	-2.00	-2.00	-2.00	-2.00	-3.00
Diluted EPS	-2.00	-2.00	-2.00	-2.00	-3.00
Basic Shares Outstanding	69.73	51.45	39.66	37.95	21.94
Diluted Shares Outstanding	69.73	51.45	39.66	37.95	21.94